SuppreMol GmbH, a German biopharmaceutical company developing novel therapeutics for the treatment of autoimmune diseases closed a 15.7 Euro ($25 million) million Series B financing round. “In particular the Company is focused on the development of soluble Fc?-Receptors (sFcRs) which are recombinant autologous therapeutic proteins endowed with a proven strong immunosuppressive potential. SuppreMol will develop […]
Less
More
ProThera Biologics Inc., an East Providence-based biomedical startup that is developing inhibitor proteins to treat inflammatory illness, such as severe infection (sepsis) and cancer, has received a $500,000 investment. ProThera - founded in 2001 by Dr. Yow-Pin Lim and Douglas C. Hixson, research scientists at Brown University’s Warren Alpert Medical School and Lifespan’s Rhode Island […]
Merrimack Pharmaceuticals, Inc., a biotechnology company focused on the discovery and development of novel treatments for autoimmune disease and cancer, today announced that it has raised $60 million in a Series F private equity financing. Proceeds from the financing will be used to advance Merrimack’s proprietary pipeline of biologic therapies targeting autoimmune disease and cancer. […]
Intrexon Corporation, a privately held life sciences company focused on biotherapeutic control systems, announced today it has closed a $25 million Series C-2 financing. “Intrexon Corporation is developing DNA control systems to enhance the safety and efficacy of existing and novel biological therapeutics. The company’s technology employs special genetic components and activator compounds to tightly […]
Anaphore Inc, a newly-formed protein therapeutics company located in San Diego, California, today announced an $8 Million financing round. Katherine Bowdish, Ph.D., a leader in protein therapeutic technologies, former President of Alexion Antibody Technologies, and Senior Vice President of Alexion Pharmaceuticals has joined as CEO. Dr. Bowdish described the platforms as “fundamental improvements in protein […]
AILERON Therapeutics, a biopharmaceutical company applying its proprietary Stapled Peptide technology to the development of breakthrough biologics for the treatment of cancer and other diseases, announced today that it has raised $10 million. AILERON Therapeutics is a biopharmaceutical company based in Cambridge, MA that is developing the first generation of peptide therapeutics directed at intra-cellular […]
Alethia Biotherapeutics announces that it has secured C$2.4 M ($2.385 mm) in financing. Alethia is a Montreal-based biotechnology company that was created in 2002 aimed at discovering tissue-specific disease targets and developing monoclonal antibodies for use as focused therapeutic in areas of unmet medical needs. Alethia’s pre-clinical programs are spear-headed by AB-0440, a protein present […]
Pieris AG, a biopharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, announced today the closing of a EUR 25 million (US$ 38 million) Series B financing round. PRS-050 Anticalin® has been designed to specifically bind and block the signalling activity of vascular endothelial growth factor (VEGF) in cancer. Optimised for extended […]
Vaccinex Inc., a Rochester, N.Y.-based developer of antibodies, has raised $25 million in Series B-2 funding. Vaccinex, Inc. is a biotechnology company engaged in the discovery and development of human monoclonal antibodies to treat a variety of serious diseases. The company’s current antibody drug development efforts are focused on cancer, autoimmune and inflammatory diseases.
Affimed Therapeutics, AG, a leading developer of next generation antibody therapeutics, today announced a second closing of Euro 5 million ($7.5 mm) to its Series B funding. This addition increases the total for the round to Euro 30 million in equity. The money raised in this Series B financing will be used to fund Affimed’s […]
biologic
BioTechnology